SpectraCure AB (publ) (SPEC.ST)
SEK 1.67
(-1.77%)
SEK 1.67
(-1.77%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.44 Million SEK | 19.29% |
| 2022 | -25.32 Million SEK | -8.5% |
| 2021 | -23.34 Million SEK | -51.5% |
| 2020 | -15.4 Million SEK | -12.58% |
| 2019 | -13.68 Million SEK | -42.4% |
| 2018 | -9.61 Million SEK | -10.5% |
| 2017 | -8.69 Million SEK | -36.48% |
| 2016 | -6.37 Million SEK | -8.29% |
| 2015 | -5.88 Million SEK | -35.4% |
| 2014 | -4.34 Million SEK | 24.18% |
| 2013 | -5.73 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.09 Million SEK | -1.79% |
| 2024 Q1 | -5.98 Million SEK | -36.89% |
| 2023 FY | -20.44 Million SEK | 19.29% |
| 2023 Q1 | -5.36 Million SEK | 16.7% |
| 2023 Q3 | -4.72 Million SEK | 20.18% |
| 2023 Q2 | -5.92 Million SEK | -10.34% |
| 2023 Q4 | -4.37 Million SEK | 7.47% |
| 2022 Q1 | -6.28 Million SEK | -5.42% |
| 2022 Q3 | -5.67 Million SEK | 19.22% |
| 2022 Q4 | -6.44 Million SEK | -13.46% |
| 2022 FY | -25.32 Million SEK | -8.5% |
| 2022 Q2 | -7.02 Million SEK | -11.93% |
| 2021 Q4 | -5.95 Million SEK | -5.34% |
| 2021 Q3 | -5.65 Million SEK | 18.69% |
| 2021 Q2 | -6.95 Million SEK | -45.72% |
| 2021 Q1 | -4.77 Million SEK | -6.9% |
| 2021 FY | -23.34 Million SEK | -51.5% |
| 2020 Q2 | -4.81 Million SEK | -27.11% |
| 2020 Q4 | -4.46 Million SEK | -90.16% |
| 2020 FY | -15.4 Million SEK | -12.58% |
| 2020 Q1 | -3.78 Million SEK | -2.1% |
| 2020 Q3 | -2.34 Million SEK | 51.19% |
| 2019 FY | -13.68 Million SEK | -42.4% |
| 2019 Q4 | -3.7 Million SEK | -21.35% |
| 2019 Q3 | -3.05 Million SEK | 26.39% |
| 2019 Q2 | -4.14 Million SEK | -49.46% |
| 2019 Q1 | -2.77 Million SEK | 13.9% |
| 2018 Q4 | -3.22 Million SEK | -67.74% |
| 2018 Q1 | -18 Thousand SEK | 99.31% |
| 2018 Q2 | -4.44 Million SEK | -24600.0% |
| 2018 Q3 | -1.92 Million SEK | 56.77% |
| 2018 FY | -9.61 Million SEK | -10.5% |
| 2017 Q1 | -1.8 Million SEK | -28.28% |
| 2017 FY | -8.69 Million SEK | -36.48% |
| 2017 Q2 | -2.12 Million SEK | -17.65% |
| 2017 Q3 | -2.15 Million SEK | -1.44% |
| 2017 Q4 | -2.59 Million SEK | -20.35% |
| 2016 Q3 | -1.61 Million SEK | 19.64% |
| 2016 Q1 | -1.31 Million SEK | 29.82% |
| 2016 Q4 | -1.41 Million SEK | 12.58% |
| 2016 FY | -6.37 Million SEK | -8.29% |
| 2016 Q2 | -2 Million SEK | -52.89% |
| 2015 Q1 | -272.7 Thousand SEK | 85.97% |
| 2015 Q4 | -1.87 Million SEK | -33.34% |
| 2015 Q3 | -1.4 Million SEK | 39.94% |
| 2015 Q2 | -2.33 Million SEK | -756.94% |
| 2015 FY | -5.88 Million SEK | -35.4% |
| 2014 FY | -4.34 Million SEK | 24.18% |
| 2014 Q1 | -613.29 Thousand SEK | 0.0% |
| 2014 Q2 | -605.56 Thousand SEK | 1.26% |
| 2014 Q3 | -1.18 Million SEK | -95.42% |
| 2014 Q4 | -1.94 Million SEK | -64.25% |
| 2013 FY | -5.73 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 73.739% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 119.75% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 119.75% |
| Arcoma AB | 2.56 Million SEK | 897.231% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 85.229% |
| BICO Group AB (publ) | -835.7 Million SEK | 97.554% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 181.839% |
| CellaVision AB (publ) | 130.3 Million SEK | 115.687% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 74.382% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 29.965% |
| C-Rad AB (publ) | 35.52 Million SEK | 157.533% |
| Duearity AB (publ) | -26.19 Million SEK | 21.951% |
| Dignitana AB (publ) | -17.36 Million SEK | -17.727% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 78.438% |
| Getinge AB (publ) | 2.41 Billion SEK | 100.847% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 69.93% |
| Iconovo AB (publ) | -45.89 Million SEK | 55.46% |
| Integrum AB (publ) | 4.03 Million SEK | 606.909% |
| Luxbright AB (publ) | -25.37 Million SEK | 19.445% |
| Mentice AB (publ) | -2.81 Million SEK | -625.63% |
| OssDsign AB (publ) | -130.49 Million SEK | 84.336% |
| Paxman AB (publ) | 8.33 Million SEK | 345.39% |
| Promimic AB (publ) | -9.22 Million SEK | -121.655% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 87.221% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 63.226% |
| ScandiDos AB (publ) | -14.64 Million SEK | -39.558% |
| Sectra AB (publ) | 428.38 Million SEK | 104.772% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 65.71% |
| Senzime AB (publ) | -134.14 Million SEK | 84.762% |
| Stille AB | 26.64 Million SEK | 176.713% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 99.469% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 122.262% |